Bimagrumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | ACVR2B |
| Clinical data | |
| ATC code | none |
| Identifiers | |
| CAS Number | 1356922-05-8 |
| ChemSpider | none |
| Chemical and physical data | |
| Formula | C6306H9732N1684O1990S46 |
| Molar mass | 142.4 kDa |
Bimagrumab (BYM338) is a human monoclonal antibody developed by Novartis to treat pathological muscle loss and weakness. On August 20, 2013 it was announced that bimagrumab was granted breakthrough therapy designation for sporadic inclusion body myositis (sIBM) by US Food and Drug Administration.[1]
Bimagrumab is currently entering Phase II development, with some research indicating clinical effects.[2] In 2016, Novartis intends to apply for FDA approval to treat sIBM patients with Bimagrumab BYM338.[3]
References
- ↑ "Novartis receives FDA breakthrough therapy designation for BYM338 (bimagrumab) for sporadic inclusion body myositis (sIBM)". Retrieved 20 August 2013.
- ↑ Treatment of sporadic inclusion body myositis with bimagrumab. Retrieved 20 April 2015.
- ↑ Novartis: Planned filings 2015 to >=2019. Retrieved 27 May 2015.
This article is issued from Wikipedia - version of the 7/15/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.